Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2024
Reporting Period: First quarter ended March 31, 2024
This filing serves as a notification that the Company issued a press release regarding its financial results for the first quarter of 2024. The detailed results are contained in Exhibit 99.1, which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, net income, operating cash flow, gross margins, debt levels, or liquidity ratios. These figures are referenced as being available in the press release (Exhibit 99.1) and the conference call materials, but are not explicitly stated within the body of this 8-K filing.
Material Changes
The filing does not detail specific material changes in financial performance compared to the prior comparable period. It only confirms the issuance of the Q1 2024 results announcement.
Guidance, Outlook, and Risks
- Management Commentary: The Company hosted a conference call on May 8, 2024, to present business and financial results. A webcast is archived on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risk Factors: Investors are directed to Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on February 27, 2024, for a comprehensive list of risks.
- Unusual Items: No unusual items or contingencies are described in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2024 revenue, net loss, and cash position figures.
- Access the archived conference call webcast at www.supernus.com for management's detailed commentary on the results.
- Consult the Form 10-K filed on February 27, 2024, for updated risk factors and full financial statements.
- Verify the Company's liquidity position and debt maturity schedule in the full quarterly report, as this 8-K does not provide those numbers.